PMID- 33089769
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1533-0338 (Electronic)
IS  - 1533-0346 (Print)
IS  - 1533-0338 (Linking)
VI  - 19
DP  - 2020 Jan-Dec
TI  - Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib 
      for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
PG  - 1533033820965587
LID - 10.1177/1533033820965587 [doi]
LID - 1533033820965587
AB  - OBJECTIVE: This study aimed to explore the efficacy and safety of using 
      transarterial chemoembolization (TACE) combined with anlotinib in patients with 
      unresectable hepatocellular carcinoma, compared with TACE alone. METHODS: This 
      was a single-center study, retrospectively recruited 82 unresectable HCC patients 
      who received either TACE alone (TA group; n = 46) or TACE combined with anlotinib 
      (TC group; n = 36) between Jan 2018 and Jan 2019. The primary outcomes were 
      progression-free survival (PFS) and overall survival (OS). While the secondary 
      outcomes were the objective response rate (ORR), the disease control rate (DCR), 
      and main complications. Log-rank test and Kaplan-Meier method was used to 
      calculate the survival difference. All statistical tests were 2-sided and P value 
      <0.05 were taken as statistically significant. RESULTS: Patients in TC group had 
      a significant higher PFS than those in TA group (7.35 months vs. 5.54 months, p = 
      0.035). Although 3-month survival rate in the 2 groups was not statistically 
      different (97.2% vs. 93.5%, p = 0.627), the survival rate at 6 months and 1 year 
      were strongly higher in TC group (83.3% vs. 56.5%, p = 0.016; 66.7% vs. 19.6%, 
      respectively, p < 0.05). Furthermore, there was a significantly higher ORR in TC 
      group, while no statistical difference existed in DCR. Neither treatment-related 
      mortality nor grade 4 adverse events (AEs) occurred. However, 2 patients in TC 
      group had grade 3 AEs (one suffered with erythra, and the other with 
      hand-foot-skin reaction), which disappeared after prompt treatment. CONCLUSION: 
      TACE combined with anlotinib is safe and may improve outcomes for unresectable 
      HCC patients comparing with TACE alone. Randomized controlled trials are 
      warranted to further evaluate treatment effects of anlotinib in HCC.
FAU - Guo, Wenbo
AU  - Guo W
AUID- ORCID: 0000-0002-8767-9401
AD  - The First Affiliated Hospital of Sun Yat-sen University, Guangdong, China.
FAU - Chen, Song
AU  - Chen S
AD  - The First Affiliated Hospital of Sun Yat-sen University, Guangdong, China.
FAU - Wu, Zhiqiang
AU  - Wu Z
AD  - The First Affiliated Hospital of Sun Yat-sen University, Guangdong, China.
FAU - Zhuang, Wenquan
AU  - Zhuang W
AD  - The First Affiliated Hospital of Sun Yat-sen University, Guangdong, China.
FAU - Yang, Jianyong
AU  - Yang J
AD  - The First Affiliated Hospital of Sun Yat-sen University, Guangdong, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
RN  - 0 (Indoles)
RN  - 0 (Quinolines)
RN  - 0 (anlotinib)
SB  - IM
MH  - Aged
MH  - Carcinoma, Hepatocellular/*drug therapy/pathology
MH  - Chemoembolization, Therapeutic/adverse effects/*methods
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Indoles/*administration & dosage
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Progression-Free Survival
MH  - Quinolines/*administration & dosage
MH  - Treatment Outcome
PMC - PMC7586029
OTO - NOTNLM
OT  - anlotinib
OT  - hepatocellular carcinoma
OT  - objective response rate
OT  - overall survival
OT  - progression-free survival
OT  - transarterial chemoembolization
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/10/23 06:00
MHDA- 2021/11/09 06:00
PMCR- 2020/10/22
CRDT- 2020/10/22 08:40
PHST- 2020/10/22 08:40 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
PHST- 2020/10/22 00:00 [pmc-release]
AID - 10.1177_1533033820965587 [pii]
AID - 10.1177/1533033820965587 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820965587. doi: 
      10.1177/1533033820965587.